Category - News

Developments

Merck KGaA gets approval for Juniper’s OneCrinone in Japan

Merck KGaA of Germany (XETRA:MRK.DE) has received approval from the Japanese Ministry of Health, Labour and Welfare for Juniper Pharmaceuticals’ (NASDAQ:JNP) OneCrinone 90 mg (progesterone) for the indication of luteal...

July 5, 2016

Developments

Can-Fite unit fails Phase 2 glaucoma trial

Can-Fite BioPharma’s (NYSE MKT:CANF; TASE:CFBI) subsidiary, OphthaliX (OTC:OPLI) released top-line results from its Phase 2 clinical trial of CF101 for the treatment of glaucoma. No statistically significant differences...

July 5, 2016

Executive Moves

Merus Labs appoints two senior executives

Merus Labs International (NASDAQ:MSLI; TSX:MSL) has appointed two key additions to its executive leadership team, effective July 1.Dr. Michael Bumby was named CFO, succeeding Andrew Patient, who has decided to leave the...

July 5, 2016

Executive Moves

Joint Corp. names Peter Holt as acting CEO

The employment of John Richards as CEO of the Joint Corp. (NASDAQ:JYNT) has been terminated by mutual agreement, effective June 30. Mr. Richards also resigned as a director. Peter Holt, who was previously COO, was...

July 5, 2016

Markets

Roth resumes coverage of CymaBay

Roth Capital Partners has resumed coverage of CymaBay Therapeutics (NASDAQ:CBAY) with a “buy” rating and $4 price target. The stock closed at $1.57 on Friday. “In our opinion, while catalysts for the next 12-to-18...

July 5, 2016

Markets

Roth resumes coverage of Galectin Therapeutics

Roth Capital Partners resumed coverage of Galectin Therapeutics (NASDAQ:GALT) with a “buy” rating and $3 price target. The stock closed at $1.52 on Friday. “In our opinion, Phase 1 data demonstrated Galectin’s GR-MD...

July 5, 2016

Markets

Stifel starts Concert Pharma at buy

Stifel launched coverage of Concert Pharmaceuticals (NASDAQ:CNCE) with a “buy” rating and 12-month target price of $23. The stock closed at $11.20 on Friday. “Our bullish thesis centers on two key pipeline assets: AVP...

July 5, 2016

Markets

JMP resumes coverage of AtriCure

JMP Securities resumed coverage of AtriCure (NASDAQ:ATRC) with a “market outperform” rating and $25 price target. The stock closed at $14.39 on Wednesday. “AtriCure is well positioned, in our view, to further develop...

June 30, 2016

Markets

Rodman starts Catalyst Biosciences at buy

Rodman & Renshaw initiated coverage of Catalyst Biosciences (NASDAQ:CLIO) with a “buy” rating and a 12-month price target of $3.50. The stock closed at $1.25 on Wednesday. Using its proprietary protease platform...

June 30, 2016

Markets

Rodman starts OpGen at buy

Rodman & Renshaw has initiated coverage of OpGen (NASDAQ:OPGN) with a “buy” rating and 12-month price target of $2.50. The stock closed at $1.56 on Tuesday. “In our view, the company’s QuickFISH assays, the latest...

June 29, 2016

Category - News

Subscribe